Earliest age to detect lifetime cardiometabolic health stratification in children [0.03%]
儿童期划分一生心血管代谢健康 stratification of lifetime cardiometabolic health in children 的最早年龄
Ville-Petteri Mäkinen,Mika Kähönen,Terho Lehtimäki et al.
Ville-Petteri Mäkinen et al.
Background and aims: Cardiovascular risk factors such as overweight and high cholesterol in childhood are predictive of high disease risk in adulthood. However, the optimal timing and scope of early prevention remains unc...
Sympathetic neurons exacerbate atherosclerosis by modulating macrophage function via the NPY/Y1R axis [0.03%]
交感神经元通过NPY/Y1R轴调节巨噬细胞功能从而加重动脉粥样硬化
Yubao Fan,Dairui Li,Qiumin Chen et al.
Yubao Fan et al.
Background and aims: Neuroimmune crosstalk is increasingly recognized in atherosclerosis, yet the contribution of the sympathetic neuron-macrophage axis remains unclear. We investigated whether and how sympathetic innerva...
Optimizing lipoprotein(a) testing for immediate clinical impact in primary prevention [0.03%]
优化脂蛋白(a)检测以期在一级预防中产生即刻的临床影响
Elias Björnson,Emil Hagström,Karin Littmann et al.
Elias Björnson et al.
Background and aims: Guidelines recommend measuring lipoprotein(a) [Lp(a)] at least once in all adults, but testing remains limited in clinical practice. We evaluated pragmatic strategies to maximize the immediate clinica...
No genetic evidence for an association of apolipoprotein A-I with cardiovascular outcomes at different LDL cholesterol levels: drug-target Mendelian randomization analyses [0.03%]
载脂蛋白A-I与低密度脂胆固醇不同水平的心血管结局的关联：用于药物靶点的孟德尔随机化分析未发现遗传学证据
Shan Luo,Yujie Ai,Stephen Burgess et al.
Shan Luo et al.
Background and aims: Exploratory post-hoc analyses of the AEGIS-II trial suggested that the efficacy of CSL112 (apolipoprotein A-I infusion) may be greater in patients with high baseline LDL-C. This genetic study aimed to...
Therapeutic targets for atherosclerotic coronary artery disease: druggable genome-wide Mendelian randomization analysis [0.03%]
动脉粥样硬化性冠状动脉疾病的治疗靶点 genome-wide Mendelian随机化分析发现可成药靶点
Wenbin Wang,Yingxian Sun,Kejia Chang et al.
Wenbin Wang et al.
Background and aims: Despite advances in treating atherosclerotic coronary artery disease (ACAD), the risk of major adverse cardiovascular events remains high. We aimed to identify potential therapeutic targets for ACAD b...
Standard modifiable cardiovascular risk factors and acute coronary syndrome free survival [0.03%]
可改变的心血管危险因素与急性冠脉综合征事件后生存率的关系
Edina Cenko,Jinsung Yoon,Maria Bergami et al.
Edina Cenko et al.
Background and aims: Recent studies suggest that patients without standard modifiable cardiovascular risk factors (SMuRFs), hypertension, hypercholesterolemia, diabetes, or smoking, may experience higher short-term mortal...
L Badimon,G Vilahur,G Mendieta
L Badimon
Atherothrombosis is a complex vascular disorder in which a thrombus forms on a vascular lesion, typically following the disruption and/or erosion of an atherosclerotic plaque. Atherothrombosis is the main pathological mechanism underlying a...
Hepatic amino acid metabolism in liver, cardiovascular, kidney and metabolic diseases [0.03%]
肝脏氨基酸代谢与肝、心、肾及代谢性疾病的关系
Emily Flam,Anne Tailleux,Joel Haas et al.
Emily Flam et al.
Amino acids are crucial metabolites with many roles in metabolism and signaling, especially in the liver. Positioned just after the portal vein, the liver controls the flow of amino acids from the diet to the body based on their degree of u...
Dianne Acoba,Isabel Gonçalves
Dianne Acoba
The concept of "vulnerable plaque" (VP) has been evolving since its introduction as an atherosclerotic plaque prone to cause cardiovascular events, such as myocardial infarction and stroke. Once defined as a thin-cap fibroatheroma prone to ...
A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials [0.03%]
一种定量方法，用于估计接受白细胞介素-6受体抑制剂silteliximab治疗的患者的血清游离白细胞介素-6：与高灵敏C反应蛋白对比及其对ZEUS、HERMES和ARTEMIS心血管结局试验的影响
Patrick Nolain,Magnus Fugger,Bibi Toft Hellinghus et al.
Patrick Nolain et al.
Background and aims: Ziltivekimab, a monoclonal antibody targeting the interleukin 6 (IL-6) ligand, is being tested in multiple cardiovascular outcome trials. However, because conventional assays for IL-6 cannot distingui...
Comparative Study
Atherosclerosis. 2026 Jun:417:120742. DOI:10.1016/j.atherosclerosis.2026.120742 2026